Resurgence of pseudomonas endocarditis in detroit, 2006-2008

Medicine

Volumn 88, Issue 5, 2009, Pages 294-301

  Reyes, Milagros P ^a,b   Ali, Ammar ^b   Mendes, Rodrigo E ^c   Biedenbach, Douglas J ^c  

^a HARPER UNIVERSITY HOSPITAL   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

^c JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CIPROFLOXACIN; FLUCONAZOLE; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; AORTA VALVE; ARTICLE; BACTERIAL ENDOCARDITIS; BLOOD CULTURE; BRAIN INFARCTION; CANDIDA ENDOCARDITIS; CANDIDA PARAPSILOSIS; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEART VALVE REPLACEMENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MEDICAL RECORD REVIEW; MITRAL VALVE; MORTALITY; NEPHROTOXICITY; OTOTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTHETIC VALVE ENDOCARDITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; TREATMENT DURATION; TRICUSPID VALVE; UNITED STATES;

ANTI-BACTERIAL AGENTS; AORTIC VALVE; ENDOCARDITIS, BACTERIAL; FEMALE; HUMANS; MALE; MICHIGAN; MIDDLE AGED; MITRAL VALVE; PSEUDOMONAS; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 70349690183     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/MD.0b013e3181b8bedc     Document Type: Article

References (44)

1. Arber N, Pras E, Copperman Y, Schapiro JM, Meiner V, Lossos IS, Militianu A, Hassin D, Pras E, Shai A, Moshkowitz M, Sidi Y. Pacemaker endocarditis. Report of 44 cases and review of the literature. Medicine (Baltimore). 1994;73:299-305.
2. Arbulu A, Asfaw I. Tricuspid valvulectomy without prosthetic replacement. J Thorac Cardiovasc Surg. 1981;82:684-691.
3. Arbulu A, Holmes RJ, Asfaw I. Tricuspid valvulectomy without replacement: twenty years' experience. J Thorac Cardiovasc Surg. 1991;102:917-922.
4. Ariano RE, Kassum DA, Meatherall RC, Patrick WD. Lack of in vitro inactivation of tobramycin by imipenem/cilastatin. Ann Pharmacother. 1992;26:1075-1077.
5. Baddour LM, Wilson WR, Bayer AS, Fowler VG Jr, Bolger AF, Levison ME, Ferrieri P, Gerber MA, Tani LY, Gewitz MH, Tong DC, Steckelberg JM, Baltimore RS, Shulman ST, Burns JC, Falace DA, Newburger JW, Pallasch TJ, Takahashi M, Taubert KA. Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America. Circulation. 2005;111:e394-434.
6. Botsford KB, Weinstein RA, Nathan CR, Kabins SA. Selective survival in pentazocine and tripelennamine of Pseudomonas aeruginosa seroype 011 from drug addicts. J Infect Dis. 1985;151:209-216.
7. Cabell CH, Barsic B, Bayer AS. Clinical findings, complications and outcome in a large prospective study of definite endocarditis: The International Collaboration on Endocarditis Prospective Cohort Study [abstract 22]. Presented at the 7th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections. Chamonix, France; June 26-28, 2003.
8. Carozza A, Renzulli A, De Feo M, Ismeno G, Della Corte A, Dialetto G, Cotrufo M. Tricuspid repair for infective endocarditis: clinical and echocardiographic results. Tex Heart Inst J. 2001;28:96-101.
9. Craig WA, Ebert SC. Continuous infusion of A-lactam antibiotics. Antimicrob Agents Chemother. 1992;36:2577-2583.
10. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of A-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17:479-501.
11. Crane LR, Levine DP, Zervos MJ, Cummings G. Bacteremia in narcotic addicts at the Detroit Medical Center. I. Microbiology, epidemiology, risk factors, and empiric therapy. Rev Infect Dis. 1986;8:364-373.
12. Donabedian H, Freimer EH. Pathogenesis and treatment of endocarditis. Am J Med. 1985;78(Suppl 3):S476-S481.
13. Drusano GL, Ambrose PG, Bhavnani SM, Bertino JS, Nafziger AN, Louie A. Back to the future: Using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007;45:753-760.
14. Duran CMG. Acquired disease of the tricuspid valve. In: Selke FW, del Nido PJ, Swanson SJ, eds. Sabiston & Spencer Surgery of the Chest. Vol.2. Philadelphia: Elsevier Saunders; 2005: 1335-1354.
15. El-Khatib MR, Wilson FM, Lerner AM. Characteristics of bacterial endocarditis in heroin addicts in Detroit. Am J Med Sci. 1976;271: 197-201.
16. Fichtenbaum CJ, Smith MJ. Treatment of endocarditis due to Pseudomonas aeruginosa. Clin Infect Dis. 2003;47:427-430.
17. Gammie JS. Invited commentary. An outstanding series of tricuspid valve operations for infective endocarditis. Ann Thorac Surg. 2007;84:1949.
18. Gavin PJ, Suseno MT, Cook FV, Peterson LR, Thomson RB Jr. Left-sided endocarditis caused by Pseudomonas aeruginosa: successful treatment with meropenem and tobramycin. Diagn Microbiol Infect Dis. 2003;47:427-430.
19. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett s Principles and Practice of Infectious Diseases. Philadelphia: Elsevier; 2005:328-356.
20. Gottardi R, Bialy J, Devyatco E, Tschernich H, Czerny M, Wolner E, Seitelberger R. Midterm follow-up of tricuspid valve reconstruction due to active infective endocarditis. Ann Thorac Surg. 2007;84:1943-1948.
21. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet. 1995;28:143-160.
22. Jimenez-Lucho VE, Saravolatz LD, Medeiros AA, Pohlod D. Failure of therapy in Pseudomonas endocarditis: selection of resistant mutants. J Infect Dis. 1986;154:64-68.
23. Karchmer AW, Gibbons GW. Infections of prosthetic heart valves and vascular grafts. In: Bisno AL, Waldvogel FA, eds. Infections Associated With Indwelling Devices. 2nd ed. Washington, DC: American Society for Microbiology; 1994:213-249.
24. Komshian SV, Tablan OC, Palutke W, Reyes MP. Characteristics of left-sided endocarditis due to Pseudomonas aeruginosa in the Detroit Medical Center. Rev Infect Dis. 1990;12:693-702.
25. Letendre ED, Mantha R, Turgeon PL. Selection of resistance by piperacillin during Pseudomonas aeruginosa endocarditis. J Antimicrob Chemother. 1988;22:557-562.
26. Levine DP, Crane LR, Zervos MJ. Bacteremia in narcotic addicts in the Detroit Medical Center. II. Infectious endocarditis: a prospective comparative study. Rev Infect Dis. 1986;8:374-396.
27. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, Bashore T, Corey GR. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30:633-638.
28. Mestres C-A, Miro JM, Pare JC, Pomar JL. Six-year experience with cryopreserved mitral homografts in the treatment of tricuspid valve endocarditis in HIV-infected drug addicts. J Heart Valve Dis. 1999;8:575-577.
29. Miyagishima RT, Brumwell ML, Jamieson WRE, Munt BI. Tricuspid valve replacement using a cryopreserved mitral homograft. Surgical technique and initial results. J Heart Valve Dis. 2000;9:805-809.
30. Morpeth S, Murdoch D, Cabell C, Karchmer A, Pappas P, Levine D, Nacinovich F, Tattevin P, Fernandez-Hidalgo N, Dickerman S, Bouza E, del Rio A, Lejko-Zupanc T, Ramos A, Iarussi D, Klein J, Chirouze C, Bedimo R, Corey R, Fowler VG Jr, and the International Collaboration on Endocarditis Prospective Cohort Study (ICE-PCS) Investigators. Non-HACEK gram-negative bacillus endocarditis. Ann Intern Med. 2007;147:829-835.
31. Mouton JW, Vinks A. Is continuous infusion of A-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother. 1996;38:5-15.
32. Myerowitz PD, Gardner P, Campbell C, Lamberti JJ, Replogle RL, Anagnostopoulos CE. Earlier operation for left-sided endocarditis in drug addicts. J Thorac Cardiovasc Surg. 1979;77:577-581.
33. Navas D, Caillon J, Gras-Le Guen C, Jacqueline C, Kergueris M-F, Bugnon D, Potel G. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics. J Antimicrob Chemother. 2004;54: 767-771.
34. Rajashekaraiah KR, Rice TW, Kallick CA. Recovery of Pseudomonas aeruginosa from syringes of drug addicts with endocarditis. J Infect Dis. 1981;144:482.
35. Reyes MP, Brown WJ, Lerner AM. Treatment of patients with Pseudomonas endocarditis with high-dose aminoglycoside and carbenicillin therapy. Medicine (Baltimore). 1978;57:57-67.
36. Reyes MP, Lerner AM. Current problems in the treatment of infective endocarditis due to Pseudomonas aeruginosa. Rev Infect Dis. 1983;5:314-320.
37. Reyes MP, Palutke WA, Wylin RF, Lerner AM. Pseudomonas endocarditis in the Detroit Medical Center, 1969-1972. Medicine (Baltimore). 1973;52:173-194.
38. Reyes MP, Reyes K. Gram-negative endocarditis. Curr Infect Dis. 2008;10:267-274.
39. Sanders CC. Cefepime: the next generation? Clin Infect Dis. 1993;17:369-379.
40. Tablan OC, Reyes MP, Rintelmann WF, Lerner AM. Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis. J Infect Dis. 1984;149: 257-263.
41. Tessier PR, Nicolau DP, Onyeji CO, Nightingale CH. Pharmacodynamics of intermittent- and continuous-infusion cefepime alone and in combination with once-daily tobramycin against Pseudomonas aeruginosa in an in vitro infection model. Chemotherapy. 1999;45:284-295.
42. Viaene E, Chanteux H, Servais H, Mingeot-Leclercq M-P, Tulkens PM. Comparative stability studies of antipseudomonal A-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother. 2002;46: 2327-2332.
43. Wieland M, Lederman MM, Kline-King C, Keys TF, Lerner PI, Bass SN, Chmielewski R, Banks VD, Ellner JJ. Left-sided endocarditis due to Pseudomonas aeruginosa. A report of 10 cases and review of the literature. Medicine (Baltimore). 1986;65:180-189.
44. Winston DJ, McGrattan MA, Busuttil RW. Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections. Antimicrob Agents Chemother. 1984;26:673-677.